OGN
Organon & Co.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Organon has 15 disclosed suppliers and 3 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
Organon & Co.
13.83
+0.02 · +0.12%
post 13.84 +0.09%
SentenceExamples of current strategic collaborations include our license agreement with Organon to commercialize XACIATO, and our arrangements with Bravado Pharmaceuticals, LLC, under which it manufactures DARE to PLAY and fulfills prescription, and Medvantx, a pharmacy services provider, acting as a lo
SentenceSales of Emgality, a medicine for the preventive treatment of migraine, increased 63% for the year ended December 31, 2025, compared to 2024, as a result of our acquisition of the distribution and promotion rights from Lilly in 2024 in certain markets outside of the United States.
SentenceUnder the terms of the agreement with Biogen, we paid an upfront payment of $51 million in July 2025, and are obligated to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments of up to $45 million from a previous in-license arrangement with Bio-Thera Solutions Ltd., the product developer for Tofidence .
OGN 10-Kaccession 0001628280-26-011125
SentenceFor the year ended December 31, 2025, we recognized $6 million in acquired in-process research and development and milestones, related to the exit of our agreement with Centergene, due to the evolving fertility landscape in China.
OGN 10-Kaccession 0001628280-26-011125
SentenceFor the year ended December 31, 2024, acquired in-process research and development and milestones of $81 million primarily represented the research and development milestones of $70 million for our agreement with Henlius and $10 million for our agreement with Cirqle, which were determined to be probable of being achieved.
OGN 10-Kaccession 0001628280-26-011125
SentenceFor the year ended December 31, 2024, acquired in-process research and development and milestones of $81 million primarily represented the research and development milestones of $70 million for our agreement with Henlius and $10 million for our agreement with Cirqle, which were determined to be probable of being achieved.
OGN 10-Kaccession 0001628280-26-011125
SentenceOn October 28, 2024, Organon acquired Dermavant, a company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology.
OGN 10-Kaccession 0001628280-26-011125
SentenceFor the year ended December 31, 2024, acquired in-process research and development and milestones of $81 million primarily represented the research and development milestones of $70 million for our agreement with Henlius and $10 million for our agreement with Cirqle, which were determined to be probable of being achieved.
OGN 10-Kaccession 0001628280-26-011125
SentenceUnder the agreement, Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration of product candidates, and the Company has an exclusive license for worldwide commercialization with certain geographic exceptions specified on a product-by-product basis.
OGN 10-Kaccession 0001628280-26-011125
SentenceOn February 19, 2026 Organon entered into an exclusive license agreement with Sebela Pharmaceuticals for the global rights to Miudella ®2 , a hormone-free copper intrauterine device ("IUD") which was approved by the FDA on February 24, 2025.
OGN 10-Kaccession 0001628280-26-011125
SentenceFor the year ended December 31, 2024, acquired in-process research and development and milestones of $81 million primarily represented the research and development milestones of $70 million for our agreement with Henlius and $10 million for our agreement with Cirqle, which were determined to be probable of being achieved.
OGN 10-Kaccession 0001628280-26-011125
SentenceIn September 2024, we entered into license and supply agreements with Centergene, pursuant to which we acquired the exclusive commercialization rights to Centergene's investigational asset, SJ02, in China.
OGN 10-Kaccession 0001628280-26-011125
SentenceSales for the year ended December 31, 2025, compared to 2024, declined 30%, due to competitive pressure in the United States, unfavorable pricing and lower tendered volume from Brazil's Ministry of Health when compared with 2024.
OGN 10-Kaccession 0001628280-26-011125
SentenceIn January 2026, the Company divested the Jada System to Laborie for an aggregate payment of up to $ 465 million, comprised of consideration of $ 440 million, subject to certain customary closing adjustments, including inventory value, plus potential earnout payments of up to $ 25 million based on the achievement of certain 2026 net sales targets.
OGN 10-Kaccession 0001628280-26-011125
SentenceIn January 2026, we divested the Jada System to Laborie for an aggregate payment of up to $465 million, comprised of consideration of $440 million, subject to certain closing adjustments, plus potential earnout payments of up to $25 million based on the achievement of certain 2026 net sales targets.
OGN 10-Kaccession 0001628280-26-011125
Linked news